Thor Medical ASA: Primary Insider Notification in Relation to Redelivery of Shares

10.9.2026 10:20:22 CEST | Thor Medical ASA | Managers' transaction

Oslo, Norway, 10 September 2026: Reference is made to the stock exchange
announcements by Thor Medical ASA (the "Company") on 3 September 2026 regarding
the successful completion of a private placement (the "Private Placement") and a
retail offering through Nordnet (the "Retail Offering").

Reference is also made to the share lending agreement entered into by and
between the Company, its shareholder Scatec Innovation AS as share lender and
Arctic Securities AS and ABG Sundal Collier ASA as managers (the "Managers"), to
facilitate delivery-versus-payment settlement in the Private Placement and the
Retail Offering (the "Share Lending Agreement").

Following the registration of the share capital increases pertaining to the
Private Placement and the Retail Offering, the Managers will today redeliver
57,291,667 new shares in the Company to Scatec Innovation AS pursuant to the
Share Lending Agreement.

Scatec Innovation AS is a close associate of chairman John Andersen. Primary
insider notifications pursuant to the EU Market Abuse Regulation article 19 are
attached.

This announcement is subject to disclosure requirements pursuant to the EU
Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act
section 5-12.

 

Contacts

Mathias Nilsen Reierth, Head of Communications and Corporate Affairs, +47 988 05
724, mathias.reierth@thormedical.com - brede.ellingseter@thormedical.com

 

ABOUT THOR MEDICAL ASA

Thor Medical is a leading supplier of high-purity isotopes to the
radiopharmaceutical industry. The Company's proprietary production platform
combines advanced separation technology with industrial-scale manufacturing
capacity to deliver a reliable, scalable and cost-efficient supply of
alpha-emitting radioisotopes. Thor Medical supports radiopharmaceutical
companies from early-stage development to commercialization enabling scale-up of
next-generation targeted cancer therapies. Thor Medical's product portfolio
includes lead-212 (Pb-212) and its precursor isotopes thorium-228 (Th-228) and
radium-224 (Ra-224). Based on naturally occurring thorium, Thor Medical's
production process requires neither irradiation nor nuclear reactors, providing
significant cost advantages while minimizing radioactive waste. Guided by its
vision to become a world-leading enabler for targeted cancer therapies, Thor
Medical is committed to improving millions of lives by powering the next
generation of precision cancer treatment with high-purity isotopes. Thor Medical
is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange under
the ticker symbol TRMED. For more information, visit www.thormedical.com -
http://www.thormedical.com.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19059005/17099/Download%20announc
ement%20as%20PDF.pdf

Primary insider notification Scatec Innovation AS.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/19059005/17098/Primary%20insider%
20notification%20Scatec%20Innovation%20AS.pdf
/19059005/17098/Primary%20insider%\
20notification%20Scatec%20Innovation%20AS.pdf\